

The Public Markets



Here's why OTC: VCEX is the must-see stock of the year. The timing couldn't be better.

We believe that timing could not get any better than this. has only just announced their introduction into the markets on June 14th...

Posted By Editor At The Public Markets

It is a brave and impassioned world for biotechnology companies focusing on cancer treatment. Science is moving at a rate never seen before and investors are finding it challenging to navigate the rapidly advancing sector. While there has been a great deal of progress in the battle against cancer, it remains the second leading cause of death in US, just behind heart disease. Vaccex operates a development stage biotechnology company that develops cancer immunotherapy products to harness the power of a patient's immune system to help remove cancer cells. We believe that their early stage and reflecting stock price make it an ideal opportunity for investors seeking maximum ROI in the booming bio-technology sector.

“ We believe that our lead product candidate, VX001, presents a unique opportunity to address the large unmet medical need in the treatment of patients with metastasized solid tumors. We expect that being a fully reporting public company will provide increased trust in the company and increased access to capital to accelerate the clinical development of VX001

— Dr. Per Horn, President and CEO, of Vaccex, Inc. ”

The market is hot with Big Pharma investing heavily in immunotherapy

With the recent \$770 million dollar acquisition of Tilos Therapeutics by Merck and the \$11 billion dollar acquisition of Array BioPharma by Pfizer, investors around the world are seeing that Big Pharma is putting “their money where their mouth is” when it comes to immunotherapy focused, bio-tech companies.

So what does this mean for the average investor? It is far more important to find a stock that is ripe for course, rather than one that is already reflecting it's perceived value. We believe that it would be considered unwise to invest after the announcement of a major acquisition. It would be far more profitable to locate a stock that is holding tremendous value, in the early course of its life. is currently looking a lot like the major players but sitting at a market capitalization that is a small fraction of its own competitors. This is clear when looking at the market caps listed below.

Where has OTC: VCEX been all this time?

We believe that timing could not get any better than this. has only **just announced their introduction into the markets on June 14th** with [this press release](#). Ever hear the expression “the early bird gets the worm?” Well, it couldn't be earlier in the morning and in our opinion, this is the shangri-la of worms (stocks) available on the market.

Leading up to now, Vaccex has been hard at work developing their leading product, VX001. VX001 is a sustained release formulation of a potent TLR7/8 agonist that works in synergy with fractionated radiotherapy (RT). VX001 is a potent stimulator of the innate immune system and intra-tumoral injection of VX001 in combination with RT causes tumor regression, long-term survival and prevention of cancer upon re-challenges in syngenic mouse models.

“ *The approach of Vaccex is unique in the growing area of cancer immunotherapy and provides a potential prolongation of life expectancy or even a cure for patients who currently have little hope of disease regression*

— Dr. Morten Albrechtsen, Clinical and Medical Advisor to Vaccex, Inc. ”

What makes vx001 so unique?

Immunotherapy treatment is nothing new. However, like the other treatments it is paired with (radiation, chemo, etc.) a potential for negative side-effects that can be challenging and even detrimental to patients. Immunotherapy, specifically, can cause a host of problematic symptoms such as systemic toxicity resulting from broad distribution of the drug as opposed to having it targeted to the intended area of the patient.

has pioneered a unique technology that could have the potential to minimize all of these risks associated with immunotherapy treatment. VX001 targets the tumor directly, lowering the overall dose of the medication. This allows there to be a low amount of medicine in the patient's system while being highly effective in the desired area.

Below are some of the negative symptoms of immunotherapy that VX001 has been designed to reduce.

Management makes the difference. Don't just bet on the horse bet on the jockey

Management:



Per Horn, MSc, MPhil, PhD

CEO

Dr. Horn has a broad background in biotech and pharma and is experienced in executive, non-executive positions, people and project management, BD activities and biotech startups with a strong interest in collaborations, organizational structure, outsourcing/insourcing, therapeutic focus and stakeholder interactions at all levels.

Medical and commercial advisors:



Jørgen Thorball, MD

- Serial life science entrepreneur and innovator
- Company expansion, strategies and investments
- 3Brain AG, ViroGates A/S [VIRO], RetiPharma A/S and many others



Morten Albrechtsen, MD, BBA

- Seasoned life science entrepreneur, executive and non-executive
- Lead launch and implementation of new treatments and technologies
- Boehringer Ingelheim, Nycomed, Amersham, Nanovi, Enkam and many others



Ed Cappabianca, BA, MBA

- Serial life science entrepreneur
- Corporate banking, venture capital, IPO and Mergers & Acquisitions
- Biocontrol, AmpliPhi Biosciences, EnXray Limited and others

We are paid to advertise the Profiled Issuer (VCEX). thepublicmarkets.com is owned by 7 Stocks, LLC and has been compensated \$100,000 by Antevorta Capital Partners LTD. for a period beginning on June 24, 2019 and ending July 22, 2019. We will update any changes to our compensation. We own zero shares of (VCEX). [Click here for the full disclaimer.](#)

Select a broker



Decisions to buy, sell, hold or trade in securities, commodities and other investments involve risk and are best made based on the advice of qualified financial professionals. Neither thepublicmarkets.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law. Nothing on thepublicmarkets.com constitutes a solicitation or recommendation to buy, sell or hold securities. Any trading in securities or other investments involves a risk of substantial losses. The practice of "Day Trading" involves very high risks and can cause you to lose substantial sums of money. "Penny stocks" can be particularly risky. Before undertaking any trading program, you should consult a qualified financial professional. Please consider carefully whether such trading is suitable for you in light of your financial condition and ability to bear financial risks. Our publications may contain information that is not accurate or complete. Opinions in our publication may also change without notice. Under no circumstances shall we be liable for any loss or damage you or anyone else incurs as a result of any trading or investment activity that you or anyone else engages in based on any information or material you receive through thepublicmarkets.com or our Services. [Click here to read the full disclaimer.](#)